Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]

Alberto Gil-Jimenez¹, Jeroen van Dorp², Alberto Contreras-Sanz³, Kristan van der Vos², Daniel J Vis¹, Linde Braaf⁴, Annegien Broeks⁴, Ron Kerkhoven⁵, Kim E M van Kessel⁶, María José Ribal⁷, Antonio Alcaraz⁷, Lodewyk F A Wessels⁸, Roland Seiler⁹, Jonathan L Wright¹⁰, Lourdes Mengual⁷, Joost Boormans⁶, Bas W G van Rhijn¹¹, Peter C Black³, Michiel S van der Heijden¹²

Affiliations

¹ Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
² Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.
³ The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
⁴ Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁵ Core Facility Genomics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁶ Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
⁷ Laboratory and Department of Urology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Universitat de Barcelona, Barcelona, Spain.
⁸ Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, The Netherlands.
⁹ Department of BioMedical Research, University of Bern, Bern, Switzerland; Department of Urology, Hospital Center Biel, Biel, Switzerland.
¹⁰ Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
¹¹ Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
¹² Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.

PMID: 36907692
DOI: 10.1016/j.eururo.2023.03.002

Published Erratum

Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]

Alberto Gil-Jimenez et al. Eur Urol. 2023 Jun.

. 2023 Jun;83(6):e165.

doi: 10.1016/j.eururo.2023.03.002. Epub 2023 Mar 10.

Authors

Affiliations

¹ Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
² Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.
³ The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
⁴ Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁵ Core Facility Genomics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁶ Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
⁷ Laboratory and Department of Urology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Universitat de Barcelona, Barcelona, Spain.
⁸ Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, The Netherlands.
⁹ Department of BioMedical Research, University of Bern, Bern, Switzerland; Department of Urology, Hospital Center Biel, Biel, Switzerland.
¹⁰ Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
¹¹ Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
¹² Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.

PMID: 36907692
DOI: 10.1016/j.eururo.2023.03.002

No abstract available

PubMed Disclaimer

Erratum for

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis DJ, Braaf L, Broeks A, Kerkhoven R, van Kessel KEM, Ribal MJ, Alcaraz A, Wessels LFA, Seiler R, Wright JL, Mengual L, Boormans J, van Rhijn BWG, Black PC, van der Heijden MS. Gil-Jimenez A, et al. Eur Urol. 2023 Apr;83(4):313-317. doi: 10.1016/j.eururo.2022.07.023. Epub 2022 Aug 11. Eur Urol. 2023. PMID: 35965206

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]

Affiliations

Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources